Drostanolone Injection 100mg/ml 10ml Vial by Genesis

Usage

1. Confirm vial integrity and read the Genesis certificate of analysis (HPLC potency + LAL endotoxin data) before first use — this confirms the active molecule is present at 100mg/ml as stated.
2. Warm the vial to room temperature (approximately 20–22°C) by holding it in your palm for 60 seconds; this reduces oil viscosity and ensures the full dose draws cleanly without air bubble entrapment.
3. Swab the rubber septum with a 70% isopropanol wipe and allow it to dry fully before needle insertion — disrupting surface biofilm prevents introducing environmental organisms into the oil matrix.
4. Draw your intended volume using a 1ml syringe; at 100mg/ml each 0.5ml graduation equals exactly 50mg, so verify your measurement against the androgen receptor activation dose you have calculated.
5. Switch to an injection-gauge needle (23–25G, 1–1.5 inch) for the actual intramuscular administration into a large muscle group (gluteus medius or vastus lateralis preferred); aspirate briefly, then inject slowly over 10–15 seconds to distribute the oil evenly and minimise post-injection pressure.
6. Log the injection date, volume drawn, and vial lot number after each administration; this record supports accurate tracking of total AR-active compound delivered across the cycle and simplifies dose adjustments based on observed receptor-level response.

Warnings

Frequently asked questions

How does drostanolone propionate bind to the androgen receptor compared to testosterone?

Drostanolone binds the androgen receptor ligand-binding domain with an affinity approximately 3–5 times greater than testosterone in competitive displacement assays, owing to its 2α-methyl-DHT structure. Unlike testosterone, it cannot be aromatised, so all receptor-level activity remains androgen-specific. Testosterone's receptor interaction is partially diluted by conversion to estradiol; drostanolone's is not, making its AR-to-dose ratio more efficient in tissues expressing aromatase.

What does the 2α-methyl modification on drostanolone actually do at the molecular level?

The 2α-methyl group blocks the enzyme 3α-hydroxysteroid dehydrogenase (3α-HSD) from metabolising drostanolone in skeletal muscle — the same enzyme that rapidly degrades native DHT in that tissue. By resisting this inactivation pathway, drostanolone remains bound to and activating the androgen receptor for longer per dose. This extended receptor occupancy is the molecular reason its anabolic effect exceeds what the underlying DHT scaffold alone would predict.

Why is drostanolone's androgen receptor pathway considered more selective than nandrolone's?

Nandrolone undergoes significant 5α-reduction to a weaker metabolite in some tissues and also binds the progesterone receptor, introducing off-target endocrine signalling. Drostanolone's 5α-reduced structure is already maximally reduced, so no further reductive metabolism occurs, and its progesterone receptor affinity is negligible. Its pharmacological action is therefore channelled almost entirely through the classical androgen receptor, producing a narrower but more predictable receptor-level effect.

How should Genesis Drostanolone Propionate 100mg/ml be stored after the vial is first opened?

After the rubber septum is first punctured, store the vial upright at 15–25°C away from direct light; refrigeration (2–8°C) extends in-use stability but is not mandatory for oil-based preparations. Use a fresh insulin-gauge needle for each draw to maintain septum integrity. The 10ml multi-dose format provides approximately 10–20 individual injections depending on protocol; the vial should be discarded within 28 days of first access in line with standard multi-dose vial guidelines.

Is 100mg/ml a meaningful concentration difference when drawing with an insulin syringe?

Yes — at 100mg/ml, a 0.5ml draw on a 1ml insulin syringe delivers exactly 50mg, making per-injection arithmetic straightforward and minimising measurement error. Higher-concentration formulations (150mg/ml or 200mg/ml) require smaller volume draws for equivalent doses, which amplifies proportional dosing inaccuracies at sub-0.3ml volumes. For every-other-day protocols where precision per injection matters, 100mg/ml with a 1ml syringe offers the most readable and reproducible draw. (2) angle_used

Manufacturer

Genesis approaches quality control for its injectable androgen line through a two-instrument verification system built around reversed-phase HPLC and LAL endotoxin assay — both conducted at finished-product stage rather than at the raw-material intake point alone. For Drostanolone Propionate 100mg/ml specifically, HPLC analysis quantifies the active ester concentration against a certified reference standard, generating a percentage deviation figure that must fall within a tightly specified acceptance window before the batch is released; any lot falling outside that window is quarantined and re-evaluated rather than released to distribution. The LAL (Limulus Amebocyte Lysate) test runs concurrently on the same batch sample, measuring endotoxin load in endotoxin units per millilitre against the parenteral limit defined by pharmacopoeial guidance — a threshold significantly more stringent than the pyrogen limits applicable to non-injectable dosage forms. These two assay results, along with the batch number and manufacturing date, are documented on the certificate of analysis that accompanies each vial. Genesis structures this documentation so that end-users, distributors, and quality-oversight bodies can trace any given vial back to its specific production record — a chain-of-identity approach that transforms the quality system from an internal audit function into an externally verifiable accountability mechanism.